Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial.
Nicholas S Teodoro, Katie R Mollan, Jessica R Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Melissa A Mischell, Lisa Rahangdale, Carla J Chibwesha
medRxiv 2026.03.14.26348308
摘要
摘要
OBJECTIVE: Determine acceptability and feasibility of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) for treatment of cervical intraepithelial neoplasia grade 2/3 (CIN2/3) in women living with HIV (WLWH). DESIGN: Double-blind, randomized, placebo-controlled Phase 2b feasibility trial. SETTING: Public-sector hospital in Johannesburg, South Africa. POPULATION: 180 WLWH aged 18+ years with CIN2/3 confirmed by LEEP and on antiretroviral therapy for ≥60 days. METHODS: Participants underwent LEEP and were randomly assigned (1:1) to receive 8 doses of adjuvant 5FU or placebo cream every other week and followed for 24 weeks. MAIN OUTCOME MEASURES: The primary outcomes were acceptability and feasibility (adherence, retention, safety, tolerability). RESULTS: Between March 2023 and January 2025, we randomized 180 WLWH. Median age was 41 years (interquartile range [IQR]: 35-45), median CD4+ count was 636 cells/mm3 (IQR: 376-873), and 98.9% were virologically suppressed.Acceptability (>94%) and adherence (>91%) were high and comparable between arms. Retention exceeded 92% in both arms, although Week 24 attendance was lower in the 5FU arm (92.2% vs. 98.9%, probability difference [PD] -6.7%, 95% confidence interval [CI] -14.4%, -0.5%). Safety events were mild, more common with 5FU, and primarily reported as Grade 1 or 2 cervical inflammation (49.2% vs. 26.7%, risk difference [RD] 22.5%, 95% CI 8.6%, 36.4%). One Grade 3 adverse event (an allergic reaction to 5FU) resulted in treatment discontinuation. CONCLUSIONS: LEEP plus adjuvant intravaginal 5FU is acceptable and feasible among WLWH in South Africa, supporting progression to a Phase 3 trial. CLINICAL TRIAL REGISTRATION: NCT05413811.
KM 提取结果
0 个 Figure · 0 个 KM 面板